RE: Sceptical18 Sep 2025 13:56
Company believe the shares are undervalued. The company reaffirmed its operational position from the August 26, 2025, trading update, noting ongoing discussions with the FDA regarding De Novo and continued work to address remaining deficiencies. Collaboration discussions are in progress with a major distributor regarding potential US and EU test distribution. The company plans to update the market with its interim results on Tuesday, September 30, 2025.